The Effect of Gegen Qinlian Decoction on Clinical Prognosis and Islet Function for Type 2 Diabetic Mellitus: A Protocol Systematic Review and Meta-analysis

Ren, Yuhang; Jia, Bo; Xiong, Peiyu; Zhong, Chun; Zhang, Peixu

doi:10.37766/inplasy2020.11.0083

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GGQL was first recorded in a famous ancient medicine treatise Shanghan Lun, compiled by Zhong-Jing Zhang in the Han Dynasty of Chinese history (202 BC-220 AD). In previous researches, it has been found that GGQL exerts a range of pharmacological activities, including anti-inflammation, antidiabetic, antioxidant, and immunoregulative effects [11][12][13][14]. Our research team has confirmed that GGQL could decrease the fasting blood glucose (FBG) in mice with diabetes and improve the oral glucose tolerance and insulin tolerance in rats with T2DM [15].…”

Section: Introductionmentioning

confidence: 56%

Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation

Bao

Sun

et al. 2022

Disease Markers

View full text Add to dashboard Cite

Purpose. Gegen Qinlian Decoction (GGQL) has been employed to treat type 2 diabetes mellitus (T2DM) in the clinical practice of traditional Chinese medicine. However, the underlying mechanism of GGQL in the treatment of T2DM remains unknown. This study was aimed at exploring the pharmacological mechanisms of GGQL against T2DM via network pharmacology analysis combined with experimental validation. Methods. The effective components of GGQL were screened, and the target was predicted by using traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP). The candidate targets of GGQL were predicted by network pharmacological analysis, and crucial targets were chosen by the protein-protein interaction (PPI) network. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were performed to predict the core targets and pathways of GGQL against T2DM. Then, T2DM mice were induced by a high-fat diet combined with streptozotocin. The model and GGQL groups were given normal saline and GGQL aqueous solution (10 and 20 g/kg/d) intragastric administration, respectively, for 8 weeks. The mice in the GGQLT groups were administered with GGQLT at 10 and 20 g/kg/d, respectively. The pathological changes in liver tissues were observed by hematoxylin-eosin staining. The protein expression of TNF-α and NF-κB was verified by western blotting. Results. A total of 204 common targets of GGQL for the treatment of T2DM were obtained from 140 active ingredients and 212 potential targets of T2DM. GO and KEGG enrichment analysis involved 119 signaling pathways, mainly in inflammatory TNF signaling pathways. Animal experiments showed that GGQL significantly reduced the serum levels of body mass, fasting blood glucose, fasting insulin, HOMA-IR, TNF-α, and IL-17. The liver pathological section showed that GGQL could improve the vacuolar degeneration and lipid deposition in the liver of T2DM mice. Mechanistically, GGQL downregulated the mRNA expression of TNF-α and NF-κB. Conclusions. This study demonstrated that GGQL may exert antidiabetic effects against T2DM by suppressing TNF-α signaling pathway activation, thus providing a basis for its potential use in clinical practice and further study in treating T2DM.

show abstract

Section: Introductionmentioning

confidence: 56%

Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation

Bao

Sun

et al. 2022

Disease Markers

View full text Add to dashboard Cite

show abstract

“…Although GQD and metformin did not suppress the FBG level after islet β-cells were extremely decreased, they are still promising medicines in treating diabetes. Firstly, GQD and metformin could be used as effective medications to treat patients in the early stage of T2D or pre-diabetes [55,56]. Furthermore, the proliferation of α-cells stimulated by GQD and metformin provided an important source for α-cell to β-cell reprogramming.…”

Section: Discussionmentioning

confidence: 99%

Metformin and Gegen Qinlian Decoction boost islet α-cell proliferation of the STZ induced diabetic rats

Jois

Cui

2022

BMC Complement Med Ther

View full text Add to dashboard Cite

Background The traditional Chinese medicine Gegen Qinlian Decoction (GQD), as well as metformin, had been reported with anti-diabetic effects in clinical practice. Objective To verify whether these two medicines effectively ameliorate hyperglycemia caused by deficiency of islet β-cell mass which occurs in both type 1 and type 2 diabetes. Methods SD rats were injected with a single dose of STZ (55 mg/kg) to induce β-cell destruction. The rats were then divided into control, diabetes, GQD and metformin group. GQD and metformin groups were administered with GQD extract or metformin for 6 weeks. The islet α-cell or β-cell mass changes were tested by immunohistochemical and immunofluorescent staining. The potential targets and mechanisms of GQD and metformin on cell proliferation were tested using in silico network pharmacology. Real-time PCR was performed to test the expression of islet cells related genes and targets related genes. Results Both GQD and metformin did not significantly reduce the FBG level caused by β-cell mass reduction, but alleviated liver and pancreas histopathology. Both GQD and metformin did not change the insulin positive cell mass but increased α-cell proliferation of the diabetic rats. Gene expression analysis showed that GQD and metformin significantly increased the targets gene cyclin-dependent kinase 4 (Cdk4) and insulin receptor substrate (Irs1) level. Conclusion This research indicates that GQD and metformin significantly increased the α-cell proliferation of β-cell deficiency induced diabetic rats by restoring Cdk4 and Irs1 gene expression.

show abstract

The Effect of Gegen Qinlian Decoction on Clinical Prognosis and Islet Function for Type 2 Diabetic Mellitus: A Protocol Systematic Review and Meta-analysis

Cited by 2 publications

References 0 publications

Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation

Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation

Metformin and Gegen Qinlian Decoction boost islet α-cell proliferation of the STZ induced diabetic rats

Contact Info

Product

Resources

About